Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 19, 2009, Pages 7957-7961

  Basu, Sudipta ^a   Harfouche, Rania ^a   Soni, Shivani ^a   Chimote, Geetanjali ^a   Mashelkar, Raghunath A ^a,b   Sengupta, Shiladitya ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

Cancer; Signal transduction

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; POLYGLYCOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ENDOCYTOSIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOMA; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUSTAINED DRUG RELEASE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MELANOMA, EXPERIMENTAL; MICE; NANOPARTICLES; NANOTECHNOLOGY; NEOPLASMS; SIGNAL TRANSDUCTION;

MUS;

EID: 66049083487     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0902857106     Document Type: Article

References (24)

1. Anonymous (2008) American Cancer Society. Cancer Facts and Figures 2008. Atlanta: American Cancer Society 2008. www.cancer.org/downloads/STT/ 2008CAFFfinalsecured. pdf
2. Downward J (2003) Targeting RAS signaling pathways in cancer chemotherapy. Nat Rev Cancer 3:11-22. (Pubitemid 37328883)
3. Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954. (Pubitemid 34716871)
4. Friday BB, Adjei AA (2008) Advances in targeting the Ras/Raf/MEK/Erk mitogen activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342-346.
5. Bos JL, et al. (1987) Prevalence of ras gene mutation in human colorectal cancers. Nature 327:293-297. (Pubitemid 17075079)
6. Brose MS, et al. (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000. (Pubitemid 35424092)
7. Sieben NL, et al. (2004) In ovarian neoplasms, BRAF but not KRAS mutations are restricted to low-grade serous tumors. J Pathol 202:336-340. (Pubitemid 38325243)
8. Peer D, et al. (2007) Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech 2:751-760. (Pubitemid 350223348)
9. Zhang L, et al. (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761-769.
10. Allen TM, et al. (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1066:29-36.
11. Yuan F, et al. (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352-3356. (Pubitemid 24225946)
12. Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M (2005) Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 25:3031-3039. (Pubitemid 41044697)
13. Alessi DR, et al. (1995) PD098059 is a specific inhibitor of the activation of mitogenactivated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489-27494.
14. Sengupta S, et al. (2005) Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Nature 436:568-572. (Pubitemid 41112931)
15. Mosqueira VC, et al. (2001) Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials 22:2967-2979. (Pubitemid 32768704)
16. Moghimi SM, Hunter CA, Murray CJ (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 53:283-318. (Pubitemid 32476118)
17. Fishburn CS (2008) The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 97:4176-4183.
18. Cui W, et al. (2000) Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol Carcinog 29:219-228. (Pubitemid 32052666)
19. Clark DL, et al. (1999) Predictive value of preclinical toxicology studies or platinum anticancer drugs. Clin Cancer Res 5:1161-1167. (Pubitemid 29233233)
20. Marks JL, et al. (2008) Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 68:5524-5528.
21. Sengupta S, et al. (2003) Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation 107:2955-2961. (Pubitemid 36736639)
22. McCubrey JA, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochemica et Biophysica Acta 1773:1263-1284. (Pubitemid 47125967)
23. Ruoslahti E, Duza T, Zhang L (2005) Vascular homing peptides with cell-penetrating properties. Curr Pharm Des 11:3655-3660. (Pubitemid 41630991)
24. Tang N, et al. (2007) Improving penetration in tumors with nanoassemblies of phospholipids and doxorubicin. J Natl Cancer Inst 99:1004-1015. (Pubitemid 47232602)